A vaccine's ability to generate long-lasting, high-affinity antibodies hinges on a delicate balance. Upon exposure to a vaccine or pathogen, B cells scramble to refine their defenses, rapidly mutating ...

A vaccine's ability to generate long-lasting, high-affinity antibodies hinges on a delicate balance. Upon exposure to a vaccine or pathogen, B cells scramble to refine their defenses, rapidly mutating ...

A vaccine's ability to generate long-lasting, high-affinity antibodies hinges on a delicate balance. Upon exposure to a vaccine or pathogen, B cells ...

Successful high-affinity B cells can proliferate under special conditions that reduce the risk of mutation. Capturing this ...

T1 Energy, the solar panel manufacturing player formerly known as FREYR, announced in its 2024 full-year report that it has ...

TAGRISSO has become a standard treatment due to its strong efficacy in both first-line and adjuvant settings. The growing prevalence of EGFR ...

New research from an international team of plant biologists, led by researchers at the VIB-UGent Center for Plant Systems ...

ImmunoGenesis doses 1st patient in phase 1/2 trial of IMGS-101 in combo with balstilimab & zalifrelimab to treat immune-excluded tumours: Houston Saturday, March 8, 2025, 18:00 Hr ...

The intrinsic factor of cell senescence, PCBP2, was identified by unlabeled quantitative proteomics, and its biological role in in vitro replication senescence of human bone marrow mesenchymal stromal ...

ImmunoGenesis has initiated the first subject dosing in a multicentre Phase I/II trial of IMGS-101 (evofosfamide), the ...